Clinical Trials Directory

Trials / Completed

CompletedNCT05353608

Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients.

Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients: a Multicenter Observational Study.

Status
Completed
Phase
Study type
Observational
Enrollment
183 (actual)
Sponsor
University Hospital, Brest · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers

Summary

A frequent complication of COVID-19 disease is pulmonary embolism (PE). Lung ventilation/perfusion (V/P) scintigraphy is a well-established test for PE diagnosis. The test is interpreted based on the recognition of wedge shaped perfusion mismatched defects. However, the ventilation procedure increases the potential risk of contamination by the aerosol secretion and the expired air. A variety of strategies have been proposed in the nuclear medicine literature regarding performance of lung ventilation scintigraphy in COVID-19 patients with suspected acute PE. However, there is currently no factual data in this specific population to support recommendations to the nuclear medicine community. The aim of this study was to assess the role of ventilation imaging when performing lung scintigraphy for suspected PE in COVID-19 patients.

Conditions

Timeline

Start date
2021-04-30
Primary completion
2021-05-31
Completion
2021-05-31
First posted
2022-04-29
Last updated
2024-08-09

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT05353608. Inclusion in this directory is not an endorsement.

Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients. (NCT05353608) · Clinical Trials Directory